tiprankstipranks
Windtree Therapeutics (WINT)
NASDAQ:WINT
US Market

Windtree Therapeutics (WINT) AI Stock Analysis

Compare
310 Followers

Top Page

WI

Windtree Therapeutics

(NASDAQ:WINT)

34Underperform
Windtree Therapeutics' overall stock score reflects significant financial and technical challenges. The persistent lack of revenue and negative cash flows highlight financial instability, while the bearish technical indicators underscore ongoing market pessimism. Although a recent strategic leadership change presents a potential upside, it has yet to materially improve the company's financial outlook.

Windtree Therapeutics (WINT) vs. S&P 500 (SPY)

Windtree Therapeutics Business Overview & Revenue Model

Company DescriptionWindtree Therapeutics, Inc. (WINT) is a biotechnology company focused on developing novel therapeutics for acute cardiovascular and pulmonary conditions. The company primarily operates in the healthcare and pharmaceutical sectors, leveraging its proprietary technologies to create solutions aimed at improving the treatment and management of life-threatening diseases. Windtree's core product lines include innovative treatments for respiratory disorders and cardiac care, with a strong emphasis on addressing unmet medical needs through clinical development and strategic partnerships.
How the Company Makes MoneyWindtree Therapeutics generates revenue primarily through the development, commercialization, and licensing of its proprietary therapeutic products. The company aims to monetize its products by pursuing regulatory approvals in key markets, leading to product sales and distribution agreements. Additionally, Windtree may engage in partnerships or collaborations with larger pharmaceutical companies to co-develop and market its therapies, which can provide upfront payments, milestone payments, and royalties. Furthermore, the company may secure funding through grants or contracts from government agencies or research institutions, contributing to its financial sustainability and growth.

Windtree Therapeutics Financial Statement Overview

Summary
Windtree Therapeutics faces significant financial challenges, characterized by an inability to generate revenue and negative profitability metrics. The balance sheet reveals a reliance on debt, reducing financial flexibility. Cash flow issues further exacerbate financial instability, raising concerns about operational sustainability. Strategic changes may be required to improve financial health.
Income Statement
20
Very Negative
The company has consistently reported zero revenue over recent years, reflecting challenges in generating sales. Gross profit is negative, indicating costs exceed any income, and net losses persist. No revenue growth rate can be calculated due to zero revenues. EBIT and EBITDA margins are negative, highlighting significant operational inefficiencies.
Balance Sheet
40
Negative
The balance sheet shows a high debt-to-equity ratio, suggesting a reliance on debt financing. The return on equity is negative, reflecting ongoing losses. The equity ratio has declined over time, indicating a reduction in financial stability. However, the total assets have been maintained, suggesting some stability in asset base.
Cash Flow
30
Negative
Operating cash flows are negative, and free cash flow is consistently negative, indicating potential liquidity concerns. The free cash flow growth rate is negative, reflecting deteriorating cash flow performance. The company relies on financing cash flows, which could pose risks if capital markets change.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
0.000.000.000.000.00198.00K
Gross Profit
-67.00K-82.00K-1.06M-869.00K-638.00K185.31K
EBIT
-25.56M-17.54M-41.33M-77.28M-30.32M-24.89M
EBITDA
-9.26M-20.16M-39.46M-76.64M-31.80M-25.87M
Net Income Common Stockholders
-9.71M-20.29M-39.21M-67.64M-30.28M-29.86M
Balance SheetCash, Cash Equivalents and Short-Term Investments
24.17M4.32M6.17M22.35M16.93M22.58M
Total Assets
29.51M32.41M37.95M74.79M112.89M118.97M
Total Debt
12.10M16.83M2.28M2.89M3.78M6.31M
Net Debt
-12.08M12.51M-3.89M-19.45M-13.15M-16.27M
Total Liabilities
16.77M29.02M27.94M32.91M43.33M44.04M
Stockholders Equity
12.74M3.39M10.01M41.88M69.55M74.94M
Cash FlowFree Cash Flow
-15.30M-13.45M-19.46M-23.94M-25.61M-24.85M
Operating Cash Flow
-15.28M-13.44M-19.45M-23.66M-25.32M-24.66M
Investing Cash Flow
-12.00K-15.00K197.00K-279.00K-291.00K13.80M
Financing Cash Flow
10.09M11.60M3.08M29.36M19.96M21.77M

Windtree Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.30
Price Trends
50DMA
3.90
Negative
100DMA
11.63
Negative
200DMA
115.19
Negative
Market Momentum
MACD
-0.97
Negative
RSI
26.30
Positive
STOCH
3.80
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WINT, the sentiment is Negative. The current price of 1.3 is below the 20-day moving average (MA) of 1.69, below the 50-day MA of 3.90, and below the 200-day MA of 115.19, indicating a bearish trend. The MACD of -0.97 indicates Negative momentum. The RSI at 26.30 is Positive, neither overbought nor oversold. The STOCH value of 3.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WINT.

Windtree Therapeutics Risk Analysis

Windtree Therapeutics disclosed 83 risk factors in its most recent earnings report. Windtree Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Windtree Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$1.58B-9.85%56.60%-403.56%
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
47
Neutral
$293.47M-526.33%14.39%
46
Neutral
$695.73M-60.44%504.79%74.24%
37
Underperform
$83.94M-409.51%19.70%
34
Underperform
$861.00K-138.34%94.78%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
WINT
Windtree Therapeutics
1.30
-367.70
-99.65%
AVDL
Avadel Pharmaceuticals
6.80
-10.33
-60.30%
ACHV
Achieve Life Sciences
2.18
-2.18
-50.00%
VSTM
Verastem
5.16
-6.70
-56.49%
KNSA
Kiniksa Pharmaceuticals
20.36
2.68
15.16%

Windtree Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and StrategyRegulatory Filings and Compliance
Windtree Therapeutics Strengthens Leadership Amid Strategic Shift
Positive
Jan 13, 2025

Windtree Therapeutics has appointed Leanne Kelly to its board of directors as an independent director and chair of the audit committee, aiming to resolve a compliance deficiency with Nasdaq’s requirements. Kelly’s extensive experience in finance and leadership across life science, technology, and e-Commerce sectors is expected to strengthen Windtree’s board as the company embarks on a new strategy to acquire small biotech firms with FDA-approved products, enhancing its market positioning.

Executive/Board Changes
Windtree Therapeutics Appoints Jed Latkin as New CEO
Neutral
Nov 14, 2024

Windtree Therapeutics, Inc. announced the retirement of Craig Fraser as CEO, effective December 2024, with Jed Latkin set to take over the role. Latkin, who brings extensive experience in finance and biotech from his previous roles at ProPhase Labs and other companies, will assume leadership with a focus on leveraging his expertise to drive the company forward. His compensation package includes bonuses and equity incentives, reflecting the company’s commitment to aligning executive interests with shareholder value.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.